CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling

• Published in: Molecular cancer Vol. 18; no. 1; pp. 150 - 24
• Main Authors: Chen, Junxin, Liu, Gang, Wu, Yizheng, Ma, Jianjun, Wu, Hongfei, Xie, Ziang, Chen, Shuai, Yang, Yute, Wang, Shengyu, Shen, Panyang, Fang, Yifan, Fan, Shunwu, Shen, Shuying, Fang, Xiangqian
• Format: Journal Article
• Language: English
• Published: England BioMed Central 29.10.2019; BMC
• Subjects: 3' Untranslated Regions; Animals; ATPases Associated with Diverse Cellular Activities - genetics; beta Catenin - metabolism; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Carrier Proteins - genetics; Cell Line, Tumor; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - metabolism; Chromatin Assembly and Disassembly; circMYO10; Circular RNA; Disease Progression; DNA Helicases - genetics; EMT; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones - metabolism; Humans; Lymphoid Enhancer-Binding Factor 1 - metabolism; Methylation; Mice; MicroRNAs - genetics; Myosins - genetics; Neoplasm Metastasis; Osteosarcoma; Osteosarcoma - genetics; Osteosarcoma - metabolism; Osteosarcoma - pathology; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA, Circular; RUVBL1; Wnt Signaling Pathway; Wnt/β-catenin signaling; Wnt/β-catenin signaling; miR-370-3p; circMYO10; Osteosarcoma; RUVBL1; Chromatin remodel; Circular RNA; EMT; Histone H4K16 acetylation
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-019-1076-1

CircMYO10 is a circular RNA generated by back-splicing of gene MYO10 and is upregulated in osteosarcoma cell lines, but its functional role in osteosarcoma is still unknown. This study aimed to clarify the mechanism of circMYO10 in osteosarcoma. CircMYO10 expression in 10 paired osteosarcoma and chondroma tissues was assessed by quantitative reverse transcription polymerase chain reaction (PCR). The function of circMYO10/miR-370-3p/RUVBL1 axis was assessed regarding two key characteristics: proliferation and endothelial-mesenchymal transition (EMT). Bioinformatics analysis, western blotting, real-time PCR, fluorescence in situ hybridization, immunoprecipitation, RNA pull-down assays, luciferase reporter assays, chromatin immunoprecipitation, and rescue experiments were used to evaluate the mechanism. Stably transfected MG63 cells were injected via tail vein or subcutaneously into nude mice to assess the role of circMYO10 in vivo. CircMYO10 was significantly upregulated, while miR-370-3p was downregulated, in osteosarcoma cell lines and human osteosarcoma samples. Silencing circMYO10 inhibited cell proliferation and EMT in vivo and in vitro. Mechanistic investigations revealed that miR-370-3p targets RUVBL1 directly, and inhibits the interaction between RUVBL1 and β-catenin/LEF1 complex while circMYO10 showed a contrary effect via the inhibition of miR-370-3p. RUVBL1 was found to be complexed with chromatin remodeling and histone-modifying factor TIP60, and lymphoid enhancer factor-1 (LEF1) to promote histone H4K16 acetylation (H4K16Ac) in the vicinity of the promoter region of gene C-myc. Chromatin immunoprecipitation methods showed that miR-370-3p sponge promotes H4K16Ac in the indicated region, which is partially abrogated by RUVBL1 small hairpin RNA (shRNA) while circMYO10 showed a contrary result via the inhibition of miR-370-3p. Either miR-370-3p sponge or ShRUVBL1 attenuated circMYO10-induced phenotypes in osteosarcoma cell lines. MiR-370-3p inhibition abrogated the inhibition of proliferation, EMT of osteosarcoma cells in vitro and in vivo seen upon circMYO10 suppression via Wnt/β-catenin signaling. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to promote chromatin remodeling and thus enhances the transcriptional activity of β-catenin/LEF1 complex, which indicates that circMYO10 may be a potential therapeutic target for osteosarcoma treatment.